Valuation: Reshape Lifesciences Inc

Market Cap 15.58M 13.51M 12.68M 11.55M 21.71M 1.49B 22.07M 149M 58.2M 745M 58.49M 57.22M 2.49B P/E 2026 *
-3.06x
P/E 2027 * -2.36x
Enterprise Value 15.58M 13.51M 12.68M 11.55M 21.71M 1.49B 22.07M 149M 58.2M 745M 58.49M 57.22M 2.49B EV / Sales 2026 *
104x
EV / Sales 2027 * 62.3x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 130K 122K 111K 209K 14.31M 212K 1.43M 560K 7.17M 563K 551K 23.93M 250K 217K 204K 185K 348K 23.86M 354K 2.39M 934K 11.96M 938K 918K 39.88M
Net income -4.89M -4.24M -3.98M -3.63M -6.81M -467M -6.93M -46.7M -18.27M -234M -18.36M -17.96M -780M -7.77M -6.74M -6.32M -5.76M -10.82M -741M -11M -74.19M -29.02M -372M -29.16M -28.53M -1.24B
Net Debt - -
Logo Reshape Lifesciences Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-